OSE Pharma has selected 70 international clinical centres to participate in its pivotal phase three clinical trial of Tedopi for patients diagnosed with advanced non-small cell lung cancer (NSCLC)
Simbec-Orion, OSE Pharma's strategic partner responsible for the management of the study, has selected the 70 expert investigators centres that will lead the multi-centre phase 3 trial.
These sites were chosen according to criteria of excellence in the field of lung cancer and their recruitment capabilities in this pathology said OSE Pharma.
Among these centres for lung cancer, OSE Pharma works in France with the Gustave Roussy Institute (Paris), in Poland with the Medical University (Gdansk), and in the United States, with the Georgetown Lombardi Comprehensive Cancer Center (Washington).
Alain Chatelin, chief medical officer, OSE Pharma, said: “Following the European regulatory approvals recently obtained in seven European countries, the European investigator centres selected to participate in our pivotal Phase 3 trial of Tedopi are ready to recruit.”